|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||112.08 - 113.45|
|52-week range||81.12 - 121.45|
|PE ratio (TTM)||34.30|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||N/A|
Edwards Lifesciences (EW) will likely ride high in Q3 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve Therapy space.
As of October 13, 2017, according to a Reuters survey consisting of 22 brokerage firms, 77.3% of the firms rated Edwards Lifesciences a "buy.”
According to Wall Street analysts’ estimates for 3Q17, Edwards Lifesciences is expected to have revenues of $8.3 billion, a YoY (year-over-year) sales growth of 12.5%.
Edwards Lifesciences (EW) has scheduled its 3Q17 earnings release for October 24, 2017. This leading player in the artificial heart valves market has been gaining momentum and trading near its 52-week ...
Edwards Lifesciences (EW) rides high on product launches as well as strength in the global Transcatheter Aortic Valve Replacement market.
Jim Cramer quickly provides his opinion to various stocks from callers, including this medical equipment company.